Joseph Meharg, MD
Pulmonary Disease · Providence, RINPI 1972556066
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 213 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by GSK at 26.3% of the total. Reporting peaked in 2023 at $866 and has fallen 56.4% since, to $377 in 2025.
Across 213 payments — averaging $19.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$895
- Mylan Specialty L.p.$549
- Sanofi$363
- Regeneron Healthcare Solutions, Inc.$337
- Boehringer Ingelheim$320
- plus $589 from 12 others
What the payments were for
- Food & beverage$4,127100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 66 | $1,092 |
| AstraZeneca(2 entities) | 53 | $895 |
| Mylan Specialty L.p. | 25 | $549 |
| Sanofi | 13 | $363 |
| Regeneron Healthcare Solutions, Inc. | 16 | $337 |
| Boehringer Ingelheim | 14 | $320 |
| Verona Pharma, Inc. | 4 | $109 |
| Teva Pharmaceuticals USA, Inc. | 4 | $88 |
| Amgen | 3 | $71 |
| Grifols USA, LLC | 3 | $69 |
| E.r. Squibb & Sons, L.L.C. | 3 | $64 |
| Boston Scientific | 1 | $49 |
| Pfizer | 2 | $40 |
| Sunovion Pharmaceuticals Inc. | 2 | $27 |
| United Therapeutics Corporation | 1 | $23 |
| Gilead | 1 | $17 |
| Novartis | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
How this compares
$4,145 in reported general payments places this provider in the 80th percentile of 59 pulmonary disease providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 84 | $71,902 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 59 | $28,005 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $15,394 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $6,555 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 120 | $2,709 |
| Wixela InhubFluticasone Propion/Salmeterol | 26 | $1,957 |
| Ventolin HfaAlbuterol Sulfate | 14 | $1,333 |
| Fluticasone Propionate | 34 | $670 |
| Montelukast Sodium | 34 | $560 |
| Pantoprazole Sodium | 14 | $136 |
| Prednisone | 15 | $74 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $1,092 | $78,45799 claims |
| Boehringer IngelheimStiolto Respimat | $320 | $28,00559 claims |
| AstraZenecaBreztri Aerosphere | $895 | $15,39425 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 59 pulmonary disease providers in Rhode Island.
Other pulmonary disease in Providence
- Christopher MullinProvidence$19K
- Rabih El BizriProvidence$12K
- Andrew FoderaroProvidence$7K
- Linda NiciProvidence$3K
- Vesna BuntakProvidence$2K
- Ahmed EidProvidence$2K
- Anthony LubinskyProvidence$344
- Debasree BanerjeeProvidence$122
- Navneet SinghProvidence$96
- Jisoo LeeProvidence$89
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.